The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
Methods Mol Biol. 2024;2823:77-93. doi: 10.1007/978-1-0716-3922-1_6.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal solid malignancy with many patients succumbing to the disease within 6 months of diagnosis. The mechanisms that underlie PDAC initiation and progression are poorly understood. Current treatment options are primarily limited to chemotherapy, which is often provided with palliative intent. Unfortunately, there are no robust biomarkers to guide treatment selection or monitor treatment response. This is concerning given the increasing incidence of this cancer. We and others have generated organoid models to explore the biology underlying PDAC with the goal of identifying new therapeutic targets. Here we provide protocols to generate a preclinical PDAC organoid model and methods to use these to define the proteomic landscape of this cancer.
胰腺导管腺癌（PDAC）是一种致命的实体恶性肿瘤，许多患者在诊断后 6 个月内死于该疾病。PDAC 发生和进展的机制尚不清楚。目前的治疗选择主要限于化疗，通常是姑息性的。不幸的是，没有强大的生物标志物来指导治疗选择或监测治疗反应。考虑到这种癌症的发病率不断增加，这令人担忧。我们和其他人已经生成了类器官模型来探索 PDAC 的生物学基础，目的是确定新的治疗靶点。在这里，我们提供了生成临床前 PDAC 类器官模型的方案和使用这些模型来定义这种癌症的蛋白质组景观的方法。
